Gilead Sciences

Gilead Sciences, a Pharmaceutical Preparation Manufacturing company headquartered in the US, reported its most recent carbon emissions for 2024. Its Scope 1 emissions were 53,856,000 kg CO2e, and its Scope 2 emissions (market-based) were 17,137,000 kg CO2e. Scope 3 emissions in 2024 were approximately 998,099,000 kg CO2e, with significant contributions from purchased goods and services (731,443,000 kg CO2e), and upstream transportation and distribution (70,029,000 kg CO2e).

Gilead Sciences is committed to significant emissions reductions. The company aims to reduce absolute Scope 1 and 2 GHG emissions by 46% by 2030 from a 2019 base year, a target validated by the Science Based Targets initiative (SBTi) and classified as consistent with keeping warming to 1.5°C. Additionally, Gilead Sciences commits to reducing absolute Scope 3 GHG emissions by 15% over the same timeframe. The company also holds a near-term ambition to achieve carbon net-zero operational GHG emissions (Scope 1 and 2) by 2030.

Earlier commitments include a goal to reduce Scope 1 and Scope 2 GHG emissions by 25% by 2025, compared with a 2016 baseline.